CHF2.885 intraday (SIX): RLF.SW Relief Therapeutics may test CHF3.20 31 Mar 2026

RLF.SW stock trades at CHF 2.885 intraday on the SIX in Switzerland as buyers nibble at a recent pullback. Volume is 66,704 shares, above the 50-day average of 41,210, which supports an oversold bounce theme. Relief Therapeutics Holding AG (RLF.SW) shows short-term strength versus its 200-day average CHF 2.61, while the company reports EPS -1.36 and a negative PE ratio. Traders should watch the next resistance near CHF 3.20 and the earnings date on 2026-04-08 for follow-through.

Intraday price action for RLF.SW stock

The market shows a measured rebound after a stretch of selling; RLF.SW stock opened at CHF 2.87, hit a low CHF 2.80, and an intraday high CHF 3.00. Current uptick is +0.87% versus the prior close CHF 2.86. Relative volume at 1.62x indicates above-average interest, typical for an oversold bounce attempt on the SIX in Switzerland.

Why oversold bounce matters for RLF.SW stock

An oversold bounce can offer a low-risk entry if momentum and volume align. RLF.SW stock has fallen from a 52-week high CHF 4.59 to a low CHF 1.65, creating a wide recovery range. Short-term traders can target the first resistance band at CHF 3.20 and a secondary target at the 50-day average CHF 2.91 as profit-taking zones.

Fundamentals and valuation for RLF.SW stock

Relief Therapeutics reports negative earnings but healthy liquidity. Key metrics include EPS -1.36, book value per share CHF 2.60, and cash per share CHF 0.99. Price-to-book is 1.11 and price-to-sales is 8.95, reflecting small-cap biotech valuation and development-stage risk. The company’s market cap is CHF 36.28M, and the current ratio 4.05 supports near-term funding flexibility.

Technical setup and trading cues

Price sits above the 200-day average CHF 2.61 and just below the 50-day average CHF 2.91, forming a classic bounce zone. Watch intraday support at CHF 2.80 and resistance at CHF 3.20. On this setup, limit entries near support with stop-loss below CHF 2.70 to control downside risk. Volume spikes confirm conviction; today’s 66,704 shares exceed the average 41,210.

Meyka AI rates RLF.SW with a score out of 100 and forecast

Meyka AI rates RLF.SW with a score out of 100: 64.54 / 100 (Grade B) — HOLD. This grade factors in S&P 500 and sector comparison, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 3-year price of CHF 3.18, versus the current CHF 2.885, implying ~10.23% upside. Forecasts are model-based projections and not guarantees. For context, sector averages show stronger margins, so RLF.SW’s biotech risks remain material.

Catalysts, risks and upcoming events for RLF.SW stock

Near-term catalysts include the earnings announcement scheduled for 2026-04-08 and any clinical or regulatory updates on RLF-100 or ACER-001 programs. Key risks are ongoing negative earnings, clinical trial setbacks, and dilution from capital raises. Monitor news flow closely and confirm any bounce with volume and follow-through.

Final Thoughts

RLF.SW stock at CHF 2.885 shows a textbook oversold bounce on the SIX with above-average volume and a clear short-term resistance at CHF 3.20. Fundamentals remain mixed: EPS -1.36 and negative margins reflect development-stage biotech risk, while a 4.05 current ratio and CHF 0.99 cash per share provide liquidity cover. Meyka AI’s forecast model projects CHF 3.18 in three years, implying ~10.23% upside from today’s price; forecasts are model-based and not guarantees. For active traders, entry near CHF 2.80 with a stop below CHF 2.70 and a first target at CHF 3.20 balances reward and risk. Longer-term investors should wait for positive clinical or earnings momentum before increasing exposure. Meyka AI provides this as an AI-powered market analysis platform insight, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.